Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803236 | 0.84 | PRF1 (0.35) | ALDH1A1 | |
| SCHEMBL2669108 | 0.80 | HTR1A (0.44) | MEN1KMT2AGRM5GAASMN1; SMN2 | |
| SCHEMBL17131111 | 0.78 | MEN1 (0.40) | MEN1KMT2AGRM5CYP11B1CYP11B2 | |
| SCHEMBL15070844 | 0.77 | CYP11B1 (0.31) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL15070852 | 0.74 | KDM4E (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13637297 | 0.72 | GRM5 (0.54) | MEN1KMT2AGRM5ALDH1A1OPRD1 | |
| SCHEMBL27244215 | 0.70 | KDM4E (0.37) | CYP11B1CYP11B2CYP19A1SMN1; SMN2HTR2A | |
| SCHEMBL24253289 | 0.69 | MAOA (0.38) | MEN1KMT2ADRD2 | |
| SCHEMBL19368987 | 0.69 | MEN1 (0.50) | MEN1KMT2AGRM5OPRD1DDB1 | |
| SCHEMBL27071821 | 0.69 | ACVRL1 (0.38) | MEN1KMT2ACYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | MEN1 2694/4885KMT2A 2921/4885GRM5 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.